Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Is The Pediatric Growth Hormone Deficiency Market Size Likely To Evolve From 2025 Through 2034?
The pediatric growth hormone deficiency market has experienced significant growth in recent years. This market is expected to expand from $3.8 billion in 2024 to $4.15 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 9.1%. Historically, this growth has been fueled by increased awareness concerning the treatment of pediatric growth disorders, enhanced diagnostic capabilities, a rise in investments dedicated to research and development of next-generation products, and a stronger public insurance scheme.
The market for pediatric growth hormone deficiency is projected to experience robust expansion over the coming years, reaching a valuation of $5.83 billion by 2029, with a compound annual growth rate (CAGR) of 8.9%. This anticipated growth during the forecast period can be attributed to several factors, including the expansion of healthcare infrastructure and improved access to treatment, progress in growth hormone therapies, increased public awareness and patient support, favorable governmental policies and health programs, and a rising incidence of PGHD. Key trends anticipated during this period encompass the introduction of new treatments, customized therapeutic approaches, advancements in existing products, the adoption of telemedicine and remote patient monitoring, and the rise of personalized medicine alongside genetic testing.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21250&type=smp
Which Factors And Drivers Are Influencing The Pediatric Growth Hormone Deficiency Market In 2025?
The rising occurrence of pediatric diseases is anticipated to propel the growth of the pediatric growth hormone deficiency market going forward. Pediatric diseases are defined as medical conditions or illnesses that primarily affect children, ranging from infancy to adolescence. The surge in pediatric diseases is largely due to environmental factors, enhanced detection methods, lifestyle changes, genetic predispositions, and increasing rates of chronic conditions and allergies among children. Pediatric diseases can contribute to pediatric growth hormone deficiency (GHD) by impacting the hypothalamus or pituitary gland, which are responsible for producing growth hormone. For instance, in March 2024, according to the United Nations Children’s Fund (UNICEF), a US-based government organization, in 2022, approximately 4.9 million children under the age of five lost their lives, averaging 13,400 deaths per day. Globally, leading causes of under-five mortality included infectious diseases such as pneumonia, diarrhea, and malaria, as well as complications from preterm birth and intrapartum-related issues. Therefore, the increasing prevalence of pediatric diseases is driving the growth of the pediatric growth hormone deficiency market.
What Are The Leading Segments Analyzed In The Pediatric Growth Hormone Deficiency Market?
The pediatric growth hormone deficiencymarket covered in this report is segmented –
1) By Type: Congenital GH Deficiency; Acquired GH Deficiency; Idiopathic GH deficiency
2) By Product: Recombinant Human Growth Hormone (rhGH); Human Growth Hormone (HGH) Analogs; Long-Acting Growth Hormones
3) By Route Of Administration: Subcutaneous; Intramuscular; Oral
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By Application: Growth Hormone Deficiency; Idiopathic Short Stature; Turner Syndrome; Small For Gestational Age; Prader Willi Syndrome; Other Applications
Subsegments:
1) By Congenital GH Deficiency: Isolated GH Deficiency; Combined Pituitary Hormone Deficiency
2) By Acquired GH Deficiency: GH Deficiency Due To Pituitary Tumors; GH Deficiency Due To Brain Injury; GH Deficiency Due To Radiation Therapy
3) By Idiopathic GH Deficiency: Primary Idiopathic GH Deficiency; Secondary Idiopathic GH Deficiency
Which Ongoing Trends Are Expected To Shape The Pediatric Growth Hormone Deficiency Market Outlook?
Leading companies in the pediatric growth hormone deficiency market are concentrating on developing innovative solutions, such as long-acting, once-weekly human growth hormone analogs, to enhance patient compliance and convenience. An extended-release, once-weekly human growth hormone (HGH) analog represents a modified version of the natural human growth hormone engineered for a longer duration of effect in the body. For example, in June 2023, Pfizer Inc., a US-based pharmaceutical company, and OPKO Health Inc., a US-based medication company, jointly introduced NGENLA (somatrogon-ghla), a once-weekly human growth hormone analog approved by the Food and Drug Administration, a US-based government agency, for treating pediatric patients aged three years and older with growth failure due to insufficient secretion of endogenous growth hormone. This novel therapy aims to improve patient adherence by reducing the frequency of injections, unlike traditional treatments which often require daily doses. Clinical trials have indicated that NGENLA provides comparable efficacy to daily growth hormone treatments, offering a more practical and manageable choice for children and their families.
Which Major Industry Participants Are Leading The Pediatric Growth Hormone Deficiency Market Growth?
Major companies operating in the pediatric growth hormone deficiency market are Pfizer Inc., Eli Lilly and Company, Novo Nordisk A/S, Genentech Inc., Merck KGaA Darmstadt Germany, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., I-Mab Biopharma Co. Ltd., Ipsen Pharma, Gedeon Richter Plc, Ferring Pharmaceuticals, Celltrion Healthcare Co. Ltd., OPKO Health Inc., Zhejiang Hisun Pharmaceutical Co., Ltd., Dong-A ST Co. Ltd., Ascendis Pharma A/S, AnkeBio, Versartis Inc., Changchun Changsheng Life Sciences Ltd.
Download The Full Report For Exclusive Market Findings:
What Are The Key Regional Factors Influencing The Pediatric Growth Hormone Deficiency Market Growth?
North America was the largest region in the pediatric growth hormone deficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pediatric growth hormone deficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Pediatric Growth Hormone Deficiency Market Report:
https://www.thebusinessresearchcompany.com/customise?id=21250&type=smp
Browse Through More Reports Similar to the Global Pediatric Growth Hormone Deficiency Market 2025, By The Business Research Company
Biosimilar Growth Hormone Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report
Parathyroid Hormones Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/parathyroid-hormones-global-market-report
Biosimilar Hormone Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model